Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of February 2025. The report documents the outcome of a special general meeting of shareholders held on February 12, 2025, which was adjourned for one week from its original date. The filing confirms that shareholders approved a proposal by the requisite majority under Israeli law and the Company's articles of association.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance update regarding shareholder approval and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the successful shareholder approval of a proposal previously detailed in a Proxy Statement filed on December 30, 2024.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. It serves solely to announce the completion of the shareholder vote and incorporates the report by reference into existing registration statements (Form F-3 and Form S-8).
Key Facts for Investor Verification
- Shareholders approved the proposal at the special meeting on February 12, 2025.
- The meeting was held following a one-week adjournment from the original date.
- Approval was granted by the requisite majority in accordance with the Israeli Companies Law.
- The specific details of the approved proposal are located in the Proxy Statement filed on December 30, 2024 (Exhibit 99.2).
- This Form 6-K is incorporated by reference into the Company's active registration statements.